Swedish Orphan Biovitrum ABSWOBY 67 Days Inventory is 267.04 as of Mar. 2026, which is 4% above its 10-year median of 255.79. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.20 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 77.8% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Swedish Orphan Biovitrum AB's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Swedish Orphan Biovitrum AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.71.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Swedish Orphan Biovitrum AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Swedish Orphan Biovitrum AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Swedish Orphan Biovitrum AB Days Inventory Related Terms
Swedish Orphan Biovitrum AB Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Days Inventory of 267.04 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 255.79. Over the past decade, Swedish Orphan Biovitrum AB's Days Inventory has ranged from 167.23 to 339.28. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #715 out of 919 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is Swedish Orphan Biovitrum AB's Days Inventory too high?
Swedish Orphan Biovitrum AB's current Days Inventory of 267.04 is near median its 10-year median of 255.79. Over the past 10 years, this metric has ranged from a low of 167.23 to a high of 339.28. The Drug Manufacturers industry median Days Inventory is 162.44. Swedish Orphan Biovitrum AB's value of 267.04 is 64.4% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #715 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #715 out of 919 companies for Days Inventory. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Days Inventory is 162.44. Swedish Orphan Biovitrum AB's value of 267.04 is 64.4% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Days Inventory has ranged from 167.23 to 339.28 over the past decade. While the company's 10-year median is 255.79 vs. the industry median of 162.44, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 162.44, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Days Inventory of 267.04 is 64.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 162.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Days Inventory is 267.04, which is near median its own 10-year median of 255.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.20, compared to a current price of $23.18 — trading 34.8% above its estimated fair value. The current Days Inventory is 267.04, which is near median its 10-year median of 255.79 and 64.4% above the Drug Manufacturers industry median of 162.44. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Days Inventory is 267.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 34.8% above its estimated GF Value™ of $17.20.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Days Inventory: 267.04 (near median its 10-year median of 255.79)
GF Value™: $17.20 vs. price of $23.18 (34.8% above fair value)
Industry Position: 64.4% above the Drug Manufacturers median (#715 of 919)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
